金花股份股价微涨0.62% 上半年净利润同比下降34.53%

Core Viewpoint - Jinhua Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, attributed to increased R&D expenses and a lack of investment gains from the previous year [1] Financial Performance - For the first half of 2025, Jinhua Co. achieved operating revenue of 241 million yuan, a year-on-year decrease of 1.9% [1] - The net profit attributable to shareholders was 6.195 million yuan, down 34.53% year-on-year [1] - R&D expenses saw a significant increase of 83.2% during the reporting period [1] - The net cash flow from operating activities was -80.93 million yuan [1] Stock Performance - As of August 21, 2025, Jinhua Co. shares closed at 8.08 yuan, up 0.62% from the previous trading day [1] - The trading volume for the day was 65,858 hands, with a transaction amount of 53 million yuan and a fluctuation of 1.74% [1] - On August 21, 2025, the net outflow of main funds was 2.3434 million yuan, accounting for 0.08% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 6.3297 million yuan, representing 0.21% of the circulating market value [1] Product Line - Jinhua Co. is engaged in the research, production, and sales of pharmaceuticals, with a product line that includes chemical drugs, traditional Chinese medicine, raw materials, and health products [1] - The company's leading product, Jintian Ge capsules, is a national Class I new drug and has become a first-line medication in orthopedic clinical practice [1] - The company also offers a range of pediatric medications, including children's cough syrup [1]